Creative Biolabs, a leading biotechnology company committed to advancing exosome therapies, harnesses the expertise of its seasoned scientists and cutting-edge technology to enhance the efficiency and convenience of experimental processes for global clients.
In the wake of stem cell replacement therapy, exosome therapy has emerged as a compelling research frontier. Traumatic brain injury (TBI) stands as a significant contributor to long-term disabilities, presenting a considerable challenge in regeneratively repairing the brain following external trauma. An exosome research expert at Creative Biolabs notes, “This has sparked a keen interest in exploring therapeutic interventions for effective repair strategies.”
“Despite the ongoing exploration of novel treatments, effective strategies for TBI remain elusive. Recognizing that exosomes produced by neural stem cells play a crucial role in the physiological and pathological changes triggered by TBI, with potential neuroregulatory and repair functions, Creative Biolabs’ research team has focused on the development of stem cell exosome (SC-Exo) therapy.”
Crucially, the paracrine mechanism of stem cells may facilitate the coordination of the regeneration process after traumatic brain injury. The expert adds, “While exosomes acting as paracrine mechanisms have been extensively studied, the beneficial effects of exosomes derived from human neural stem cells (hNSC-derived exosomes) have been relatively underexplored.”
SC-Exo therapy has emerged as a promising application for tissue injury repair, and Creative Biolabs’ comprehensive SC-Exo platform provides robust support for SC-derived exosome extraction, identification, profiling, as well as in vitro and in vivo functional analysis.
“The early stages of developing TBI treatment strategies demand substantial technical and talent support, and further exploration is essential to discerning the advantageous role of exosomes relative to parent cells in TBI. Creative Biolabs’ development platform boasts experts in the exosome field and relevant technologies, instilling confidence in our ability to excel in this sector.”
As an example, Creative Biolabs’ exosome characterization technology has been finely tuned through its Nanosight™ platform, employing exosome-based nanoparticle tracking analysis (NTA) to visualize and measure nanoparticles ranging from 30 nm to 1,000 nm. The Nanosight™ platform also offers fluorescence nanoparticle tracking analysis (fl-NTA), enabling precise size, counting, and phenotype analysis of exosomes. “Creative Biolabs tailors nanoparticle tracking analysis or fluorescence NTA with distinct exosome labeling schemes based on the client’s experimental objectives.”
For further details on the therapeutic development strategies offered by Creative Biolabs for traumatic brain injury, please visit https://www.creative-biolabs.com/exosome/.
About Creative Biolabs
With a wealth of theoretical and practical experience in exosome research, Creative Biolabs is confident in providing a diverse range of exosome-related services. These include SC-derived exosome analysis, exosome drug delivery, and exosome gene modification, catering to the varied experimental needs of clients worldwide.